sarafloxacin has been researched along with Staphylococcal Infections in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bower, RR; Chu, DT; Fernandes, PB; Jarvis, KP; Ramer, NR; Shipkowitz, N | 1 |
| Adams, KR; Mader, JT; Morrison, LT | 1 |
2 other study(ies) available for sarafloxacin and Staphylococcal Infections
| Article | Year |
|---|---|
In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enterobacteriaceae Infections; Escherichia coli Infections; Female; Fluoroquinolones; Half-Life; Immunosuppression Therapy; Klebsiella Infections; Mice; Norfloxacin; Piperazines; Proteus Infections; Pseudomonas Infections; Pyelonephritis; Quinolines; Salmonella Infections, Animal; Staphylococcal Infections; Streptococcal Infections | 1986 |
Comparative evaluation of A-56619, A-56620, and nafcillin in the treatment of experimental Staphylococcus aureus osteomyelitis.
Topics: Animals; Anti-Bacterial Agents; Bone and Bones; Ciprofloxacin; Fluoroquinolones; Nafcillin; Osteomyelitis; Rabbits; Random Allocation; Staphylococcal Infections; Staphylococcus aureus; Tissue Distribution | 1987 |